World Drug Delivery and Formulation Summit

Professor Istvan TOTH is Chair in Biological Chemistry & Professor of Pharmacy, The University of Queensland (UQ), Brisbane, Australia; Affiliated Professorial Research Fellow and Group Leader, Institute of Molecular Biosciences, UQ. He graduated with a degree in Chemical Engineering from the Technical University, Budapest, Hungary in 1969 and was awarded his PhD in 1972 for research in Alkaloid Chemistry. In 1994 he was awarded a DSc for his work on drug delivery. Prof. Toth moved from the School of Pharmacy at the University of London to the University of Queensland in 1998, and leads a productive medicinal chemistry research group (presently 30 members). He is an elected RACI Fellow, Fellow of the Queensland Academy of Arts and Sciences and Fellow (External) of the Hungarian Academy of Sciences. In 2009 he was awarded the Adrian Albert award for sustained and outstanding research in medicinal biochemistry. He has over 400 peer-reviewed publications (>500 citations/year since 2012), 44 patents, and a strong record in research commercialization.His research has attracted over $84 million in competitive grants, research contracts and investment funds in the past 10 years, including an NHMRC Program grant, which is now in its fourth successive 5-year term and a recent NHMRC Project Grant.

My Medicinal Chemistry Group major interest is drug delivery, including Peptides, genes and vaccines.

Jurgen Lademann graduated from the Moscow Lomonosov State University in 1980. 1991 he received the Assistant Professorship from the University of Jena, Germany. From 1993 to 1995 he headed the Medical Center of Sensor Technology at the University of the Armed Forces Germany. In 1996 Jurgen Lademann joined the Charite Universitatsmedizin Berlin and was appointed Director of the Center of Experimental and Applied Cutaneous Physiology. In 2001 the Charite appointed him full professor of Dermatology. He is the Vice President of the IFSCC and the editor of the Journal Skin Pharmacology and Physiology. He authored more than 600 peer-reviewed articles.

Dermatology/skin physiology. Drug delivery/penetration pathways/nanoparticles. Skin aging strategies/sunscreen developments / UV, Vis and IR protection. Interaction of antioxidants and free radicals in skin. Development and application of optical noninvasive methods for diagnostics in dermatology and cosmetics.

Syed Askari, PhD, is the Founder, President and CEO of Maculus Therapeutix, an ENT medical device/drug delivery company. Previously he founded Medicus Biosciences, and launched two wound healing products, SutureSeal and HyFlex.Syed holds more than 25 patents/patents applications. Syed has a PhD in Organic Chemistry from the University of British Columbia and has completed his post doctoral work at UCLA and UCSB under Prof Wudl and Prof Heeger Nobel Laureate (year 2000) labs.

Syed's technical expertise and area of research include localized drug delivery technology to treat multiple clinical indications using in vivo polymerizable biomaterials.

Dr. Lakshmi Prasanna Kolluru is currently working as Sr. Formulation Scientist at Medefil, Inc, a generic pharmaceutical company in USA. She is responsible for leading product development project teams all the way from kick-off to product approval. Prior to joining Medefil, Dr. Kolluru served in formulation, analytical and clinical development groups across brand pharma, generic pharma and contract research organizations. She graduated with a PhD in Pharmaceutical Sciences from Mercer University, Atlanta, GA. Her thesis research focusing on development of novel targeted drug delivery system for tumor theragnosis has been recognized internationally by American Association of Pharmaceutical Scientists (AAPS) for excellence in graduate research. In addition to her active research, Dr. Kolluru serves as an editorial board member and peer-reviewer for several international journals. She is also routinely invited to serve as a speaker and moderator for international conferences on pharmaceutical nanotechnology, formulation development and drug delivery.

Parenteral Formulation Development, Targeted Drug Delivery, Nanotechnology based Drug Delivery and Generic Product Development.

Heather Sheardown is a Professor in the Department of Chemical Engineering with a cross appointment to the Department of Pathology and Molecular Medicine and an adjunct appointment with the School of Optometry at the University of Waterloo. She holds a Tier 1 Canada Research Chair in Ophthalmic Biomaterials and Drug Delivery and has published more than 140 peer reviewed papers on this subject. She is currently the Scientific Director of C20/20, an ORF funded incubator aimed at the commercialization of ophthalmic biotechnologies. Sheardown was previously the Scientific Director of the 20/20 NSERC Ophthalmic Materials Research Network which brought together 12 researchers and more than 10 companies aimed at the early stage development of novel materials based treatments for ophthalmic conditions. Sheardown is the Associate Director of Biomedical Engineering and Advanced Manufacturing (BEAM), a McMaster partnership with the Fraunhofer IZI which partners with companies for incubation and commercialization of cell based therapies, diagnostics and biomaterials. She holds 18 patents or provisional patents and is currently the Chief Scientific Officer of 20/20 Optim Eyes, a McMaster based spin out focused on developing and commercializing a micelle based technology developed in her laboratory. She runs a large and vibrant research group with more than 10 post doctoral fellows, and graduate students

Drug delivery - Anterior Eye Drug delivery - Posterior Eye Contact Lens IOLs In Vivo Ocular Testing

Dr. Tathagata Dutta is a very senior Scientist with two decades of experience in industry and academia. He has served as Chief Scientific Officer (CSO) & Head R&D of several multinational Pharmaceutical Companies across the globe. He has been accoladed with several National and International Awards and Honours. He has published more than 50 international papers in reputed journals, several patents and had authored several book chapters. He is the founder Managing Director & CEO of Etico Lifesciences.

His research interests include novel drug delivery systems, parenteral formulations, depot injections, dendrimers, polymer bioconjugates, nanotechnology, gene delivery, and RNAi therapeutics.

Mohamad Abadelah has completed his degree in Pharmacy before joining the University of Huddersfield in 2011 to study for a Master degree in the pharmaceutics and pharmaceutical analysis. After completing his master degree with distinction and awarded the Queen Elizabeth II diamond Jubilee Prize for his outstanding achievement, he decided to pursue his Ph.D. in the inhalation field under the supervision of both Prof Henry Chrystyn and Dr El Hassane Larhrib. His work focuses on dose emission aerodynamic characteristic from dry powder inhalers (DPIs) and evaluation of the performance of some commercially available DPIs using both In-vitro and ex-vivo methodologies. He has presented his research nationally and internationally at different conferences including UK Pharm.Sci, AAPS, DDL, PDDS and ERS. Mohamad is also involved in teaching and supervision of undergraduate and MSc research projects in the pulmonary drug delivery. In December 2017, He has been awarded his PhD in pharmaceutical science from the University of Huddersfield following his excellent research on the characterization of inhaler devices performance for asthma and COPD patients.

Pulmonary Drug Delivery

Anthony Pettigrew,serves as Vice President of Pharmaceutical Development at Novaliq GmbH. He is a highly experienced chemist and manager, with over 15 years of pharmaceutical experience. Initially, he joined Novaliq GmbH in 2012 as Chief Protein Chemist; however in 2013, he was promoted to Director of New Products.Prior to joining Novaliq, he had built up a solid background in the biotech field as his previous experience included leadership positions in the Biopharma Application Development group at Novozymes Biopharma A/S DK and within Analytical Development/Quality Control at Veloxis A/S DK. Pettigrew graduated as a chemist at Liverpool John Moores University (1993) and later earned his MSc in Analytical Chemistry (1995) from the University of Huddersfield.

Drug delivery technology based on Semi-Fluorinated Alkanes (SFA) particularly in the area of formulation of biopharmaceuticals.

In 2008, Dalia Yousif received her bachelor degree in pharmaceutical sciences from the faculty of pharmacy, Cairo University (Egypt) with a very good grade with honors. In 2014 received a diploma in clinical research from Harvard medical school-USA . In 2017 she received master of clinical research from Dresden international university-Germany. She worked since 2008 in the children cancer hospital -Egypt which is a JCI accredited hospital as a clinical pharmacist where she practiced and performed the duty of oncology clinical pharmacist, senior critical care pharmacist, supervisor hematopoietic stem cell transplantation pharmacist. As officer nutrition pharmacist ,She established the clinical nutrition department in the hospital. She is a freelance lecturer for clinical pharmacy and nutrition in several Egyptian universities. She is a mentor for several online courses in clinical research, statistics and data management. She is a peer reviewer to several scientific journals ( Blood, Trials, journal of research in pharmacy practice ,journal of European hospital pharmacy)and a board member of the ( international journal of medical and pharmaceutical sciences) She is a member of various international societies :pediatric oncology eastern and Mediterranean group( POEM),European society of oncology pharmacy (ESOP),international oncology nutrition group(IPONG),nutrition working group of the SIOP(SIOP PODC nutrition) and international society of pediatric oncology -Africa(SIOP Africa).

Clinical trials

Behzad Nili has completed his PharmD/PhD at the age of 27 years from Turin University, School of Pharmcey, Italy and thought at SUMS Shiraz University School of Medical Sciences, in both Departments of Pharmaceutics and Medicinal Chemistry, for several years. He has been working for Nano Drug Delivery, since 2004.

He has developed different colloidal and polymeric delivery system prototypes, with a rare, in colloidal systems, combination of high encapsulation, along with tailored zero order kinetics and prolonged/extended release.

Dr. Lee is Executive Vice President of Pharmaceutical Development Services at Particle Sciences, a Lubrizol Advanced Materials, Inc. company, a pharmaceutical contract development and manufacturing organization (www.particlesciences.com). He provides direction and is involved with product and business development. Before joining Particle Sciences, Rob held senior management positions at Novavax, Inc., Lyotropic Therapeutics, Inc., and Imcor Pharmaceutical Co. He holds BSs in Biology and Chemistry from the University of Washington and a PhD in Physical Bioorganic Chemistry from the University of California, Santa Barbara. Rob has published articles in numerous peer-reviewed journals and five book chapters plus holds over two dozen issued patents or provisional patent applications.

My research interests are in drug delivery technologies, including nano-technology-based systems; CMC; and technology evaluation.

Michael O'Rourke has over 30 years drug delivery experience across ophthalmology, periodontal and pulmonary markets in sales, marketing, product launch, strategy development and global commercialization. In 2009 he founded Scotia Vision, a specialized ophthalmic consulting company with extensive expertise in global ocular drug delivery commercial and product development strategies. Career experience includes senior positions with several global leading organizations and start-ups, including 3M, Alza, Chiron Vision, Bausch + Lomb, GrayBug and Re-Vana Therapeutics. His unique global ocular drug delivery experience includes launching the world's first intra ocular drug delivery technology in Europe, Vitrasert, and the world's second, Retisert, in the USA. He's managed 28 brands, led 13 product launches, structured/negotiated 12 strategic business deals and has been a team member in 18 device/drug approvals. Michael is from Glasgow Scotland but is now based in Tampa Florida. He was recently elected into the Global Scot "Hall of Fame", for supporting and advising Scottish start ups and existing organisations in the Life Sciences and other sectors including music with the Royal Scottish National Orchestra.

My research interest is in the development & commercialization of ocular drug delivery systems for blinding eye diseases.

As chief executive officer, Dr. Kautzmann oversees administration and technical development. He has 38 years of professional experience and specializes in Mathematics and Theoretical Computer Science. He attributes his success to his heritage and education. Prior to establishing Real Data, he worked for Honeywell Information Systems, The Boeing Consulting Division of The Boeing Corporation, and The MITRE Corporation at NASA - Johnson Space Center.Dr. Kautzmann received a Ph.D. in Philosophy in 1977 and a Ph.D. in Mathematics in 1983. He has won several refereed conferences including Best Paper Awards from the Artificial Intelligence and Expert Systems Division of the Instrument Society of America at NASA - JSC. He is a member of Sigma Xi, a Senior Member in the Institute of Electrical and Electronics Engineers [IEEE}, the American Institute of Aeronautics and Astronautics [AIAA], the Instrument Society of America [ISA], the American Mathematical Society, the American Statistical Association, The New York Academy of Science and several international mathematical societies. He is a member of 27 national honor societies.

Analytics, Data Integration, Other, Big Data, Data Science

BOAMAH COLLINS is a Ghanaian by birth and nationality.He is a medical student currently studying in Ivano-Frankivsk national medical university, Ukraine.

His hobbies are reading and traveling to do volunteer work if he get the opportunity.And also was part of the pass executive member of European Medical Student Association , Ukraine as and organizing secretary and now as part of the executive board. Future goal is to become a Public Health specialist.